Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents

Author(s): Xing Lu, Hong Liang*, Chris Orvig, Zhen-Feng Chen*

Journal Name: Current Molecular Medicine

Volume 21 , Issue 5 , 2021

Become EABM
Become Reviewer
Call for Editor


Myeloid cell leukemia 1 (Mcl-1) is a member of the Bcl-2 family of proteins with anti-apoptotic activity. It plays a key role in the regulation of the intrinsic pathway of apoptosis. Moreover, Mcl-1 is correlated with the progression and drug-resistance of various cancers. The development of inhibitors of Mcl-1 may provide effective cancer therapies. While the inhibitors of other Bcl-2 anti-apoptotic proteins have been well explored, the discovery of Mcl-1inhibitors with high selectivity has been challenging. In this review, we summarize the recent literature on small molecule and peptide inhibitors of Mcl-1, which are divided into different types including peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, quinoline derivatives, S63845, AZD5991, AMG176, etc. Their biological activities are also summarized. Mcl-1 is a valid drug target and inhibition of Mcl-1 with a small molecule inhibitor is a promising strategy for cancer therapy.

Keywords: Apoptosis, Antitumor agents, Anti-apoptotic proteins, Bcl-2 family proteins, Myeloid cell leukemia 1 inhibitor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Page: [426 - 439]
Pages: 14
DOI: 10.2174/1566524020666200929121016
Price: $95

Article Metrics

PDF: 19